EDAN

About EDAN

Established in 1995 and headquartered in Shenzhen, China, Edan Instruments, Inc. (SHE: 300206) is a publicly-traded company engaged in the research, development, manufacture, and sale of medical electronic equipment and in-vitro diagnostic products. The company was founded by Zhang Hao, who currently serves as Chairman and CEO. Originating from Shenzhen Anko, a prominent high-tech medical device company, Edan's founders identified a market need for more economical medical imaging solutions.

Edan operates on a business-to-business model, serving healthcare providers globally, including hospitals and clinics in over 170 countries. The company generates revenue through the direct sale of its extensive product portfolio, distributed through a global network. Its financial performance shows significant growth, with a reported trailing twelve-month revenue of $251 million as of March 2025. The firm has demonstrated a strong commitment to R&D, with investment in this area averaging over 20% of revenue in recent years, fostering a robust pipeline of new technologies.

The company's offerings are diversified across several key segments: Patient Monitoring, Diagnostic ECG, Obstetrics & Gynecology (OB/GYN), Ultrasound Imaging, In-Vitro Diagnostics (IVD), Point-of-Care Testing (POCT), and Veterinary care. A significant milestone was its entry into the ECG market in 2005, and by 2006, it became a leading exporter of ECG equipment. Key products include the elite series of patient monitors, Acclarix ultrasound systems, i-series ECG machines, F-series fetal monitors, and various hematology and blood gas analyzers. Edan has expanded its global footprint by establishing multiple international subsidiaries and R&D centers, including locations in the US, Germany, and Russia, to better serve its international client base.